SCHEMBL2237040

SCHEMBL2237040

COC(=O)NN(C(=O)Oc1ccccc1)c1ccc(C)cc1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGES O14684 2/20 0.48
ALDH1A1 P00352 5/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
TDP1 Q9NUW8 2/20 0.47
MAPT P10636 2/20 0.47
KDM4E B2RXH2 1/20 0.47
THRB P10828 1/20 0.47
GFER P55789 1/20 0.47
ATM Q13315 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
NPC1 O15118 1/20 0.40
HPGD P15428 1/20 0.40
HTT P42858 1/20 0.40
RAB9A P51151 1/20 0.40
PAX8 Q06710 1/20 0.40
USP2 O75604 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2234801 0.91 PTGES (0.56) PTGESALDH1A1MEN1KMT2ATDP1
SCHEMBL2236288 0.87 PTGES (0.47) PTGESALDH1A1MEN1KMT2ATDP1
SCHEMBL2234591 0.87 L3MBTL1 (0.48) PTGESALDH1A1MEN1KMT2ATDP1
SCHEMBL28793433 0.84 PTGES (0.44) PTGESALDH1A1MEN1KMT2ATDP1
SCHEMBL27842471 0.83 SMN1; SMN2 (0.43) KDM4ETHRBSMN1; SMN2NPC1HPGD
SCHEMBL2233608 0.83 ALDH1A1 (0.57) PTGESALDH1A1MEN1KMT2ATDP1
SCHEMBL2234676 0.82 L3MBTL1 (0.54) PTGESALDH1A1MEN1KMT2ATDP1
SCHEMBL27859909 0.81 MTNR1A (0.47) PTGESALDH1A1MEN1KMT2ATDP1
SCHEMBL2236717 0.80 ALDH1A1 (0.53) PTGESALDH1A1MEN1KMT2ATDP1
SCHEMBL2232497 0.79 MAPT (0.41) PTGESMEN1KMT2AMAPTATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299264-B2 Method for producing oxadiazolinone compound and intermediate thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-10-30 US disclosed
US-20110207936-A1 METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-25 US disclosed
EP-2357167-A1 METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF Sumitomo Chemical Company, Limited (JP) 2011-08-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207936-A1 METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF AHR, CYP1B1, AR PTGES 1865/4885ALDH1A1 50/4885MEN1 2516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.